Where’s the Cardiogenic Shock Treatment Data?
Looking to Real-world Evidence in Cardiogenic Shock
“There’s an inherent conflict of interest between the clinician and the scientist,” he tells interviewer Dr. Cathy Jeon. He explains that clinicians facing the life and death situation of cardiogenic shock are not willing to randomize these patients to treatment. He describes an attempted study in 2007 where shock patients would have been randomized to either Impella® or balloon pump, but physicians wanted to use their own training and experience and, as Dr. O’Neill states, “they really weren’t willing to toss the coin.” So, the study didn’t happen.
Dr. O'Neill explains that the approach he’s taken with the National Cardiogenic Shock group follows the manner in which the military handles battlefield trauma. He emphasizes that between the Korean War and the war in Afghanistan, there was an improvement in survival from traumatic injuries from about 60% to 95%. "There's no randomized trial. They realized that they had to get to people early, had to treat them early, and had to have definitive care. And we've taken that approach rather than trying to do randomized trials."
Dr. O’Neill explains that the cardiogenic shock guidelines laid out as part of the NCSI, identify AMI cardiogenic shock patients based on historical controls, manage patients following a defined protocol, collect data, and measure outcomes. “And we’ve shown that survival has increased from 50% in the previous balloon pump PCI experience to over 75%.”
Dr. O’Neill tells Dr. Jeon that a lot of data is available from INOVA, NCSI, the IQ database, and the cVAD registry. “So, I think that in the near future we’re going to have multiple, well-done, prospective registries, which is going to give us a very good evidence base for the use of hemodynamic support.”
He concludes his interview with Dr. Jeon by stating, “I think that probably the most important message is, if you really want to do something in your hospital, in your community, track your outcomes. How are you doing in shock? Rather than waiting to be spoon fed data from a randomized trial, look at your own outcomes.”
- INOVA Heart and Vascular Recovery Initiative
- Updates from the Cardiogenic Shock Working Group
- New Data from NCSI Demonstrate 72% Survival with 98% Native Heart Recovery
To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: abiomed.com/important-safety-information